XFOR X4 Pharma: רווח למניה בשנים עשר החודשים האחרונים

The success of X4 Pharmaceuticals (XFOR) is based on regulatory approval of therapies for rare pathologies and insurance coverage. A monopoly in the treatment of WHIM syndrome provides the company with exceptional pricing power, while R&D relies on third-party contractors (CRO/CMO). Historical dynamics on the GURU.Markets chart for net income per share over 12 months show a trend where the -0.66 mark characterizes this parameter.

EPS TTM measures the actual profit generation efficiency available to the holder of a single security. Analyzing the net income per share over the trailing twelve months (TTM) allows investors to filter out volatility and identify the long-term earnings trend. The metric is calculated as the ratio of total annual net income to the number of shares outstanding. For X4 Pharmaceuticals (XFOR), this reflects the value of R&D investments. A stable core of scientists and the hiring of commercial experts provide the foundation for the future growth of this metric.